logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 20 of 20 Items
Showing 1 - 20 of 20 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

Journal Article
|
Commentary

Caring for adolescents and young adults with tuberculosis or at risk of tuberculosis: Consensus statement from an international expert panel

Chiang SS, Waterous PM, Atieno VF, Bernays S, Bondarenko Y,  et al.
2023-03-01 • Journal of Adolescent Health
2023-03-01 • Journal of Adolescent Health
Journal Article
|
Research

Tuberculosis diagnosis and preventive monotherapy among children and adolescents exposed to rifampicin-resistant tuberculosis in the household

Apolisi I, Cox HS, Tyeku N, Daniels J, Mathee S,  et al.
2023-02-21 • Open Forum Infectious Diseases
2023-02-21 • Open Forum Infectious Diseases
BACKGROUND
Children and adolescents with household exposure to multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) are at high risk of developing TB disease. Tuberculosis pre...
Journal Article
|
Research

Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa

Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S,  et al.
2021-08-30 • Antimicrobial Agents and Chemotherapy
2021-08-30 • Antimicrobial Agents and Chemotherapy
Rifampicin mono-resistant TB (RMR-TB, rifampicin resistance and isoniazid susceptibility) constitutes 38% of all rifampicin-resistant TB (RR-TB) in South Africa and is increasing. We aim...
Journal Article
|
Commentary

How COVID-19 could benefit tuberculosis and HIV services in South Africa

Keene CM, Mohr-Holland E, Cassidy T, Scott V, Nelson AM,  et al.
2020-09-01 • Lancet Respiratory Medicine
2020-09-01 • Lancet Respiratory Medicine
Journal Article
|
Letter

A positive COVID-19 test is associated with high mortality in RR-TB-HIV patients

Mohr-Holland E, Daniels J, Douglas-Jones B, Mema N, Scott V,  et al.
2021-05-01 • International Journal of Tuberculosis and Lung Disease
2021-05-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Research

Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study

Cox HS, Salaam-Dreyer Z, Goig GA, Nicol MP, Menardo F,  et al.
2021-11-01 • Lancet Microbe
2021-11-01 • Lancet Microbe
BACKGROUND
South Africa has a high burden of rifampicin-resistant tuberculosis (including multidrug-resistant [MDR] tuberculosis), with increasing rifampicin-monoresistant (RMR) tube...
Journal Article
|
Research

Early mortality during rifampicin-resistant TB treatment

Mohr-Holland E, Daniels J, Reuter A, Rodriguez CA, Mitnick CD,  et al.
2022-02-01 • International Journal of Tuberculosis and Lung Disease
2022-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Data suggest that treatment with newer TB drugs (linezolid [LZD], bedaquiline [BDQ] and delamanid [DLM]), used in Khayelitsha, South Africa, since 2012, reduces mortality ...
Journal Article
|
Case Report/Series

Outcomes of children born to pregnant women with drug-resistant tuberculosis treated with novel drugs in Khayelitsha, South Africa: a report of five patients

Mohr-Holland E, Daniels J, Furin J, Loveday M, Mudaly V,  et al.
2021-05-01 • Pediatric Infectious Disease Journal
2021-05-01 • Pediatric Infectious Disease Journal
This brief report presents a series of 5 pregnant women treated for rifampicin-resistant tuberculosis with the novel drugs bedaquiline, delamanid, and linezolid as part of an optimized b...
Journal Article
|
Research

Implementing a substance-use screening and intervention program for people living with rifampicin-resistant tuberculosis: pragmatic experience from Khayelitsha, South Africa

Reuter A, Beko B, Memani B, Furin J, Daniels J,  et al.
2022-01-31 • Tropical Medicine and Infectious Disease
2022-01-31 • Tropical Medicine and Infectious Disease
Substance use (SU) is associated with poor rifampicin-resistant tuberculosis (RR-TB) treatment outcomes. In 2017, a SBIRT (SU screening-brief intervention-referral to treatment) was inte...
Journal Article
|
Research

Rifampicin-monoresistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa

Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S,  et al.
2021-10-18 • Antimicrobial Agents and Chemotherapy
2021-10-18 • Antimicrobial Agents and Chemotherapy
Rifampin monoresistance (RMR; rifampin resistance and isoniazid susceptibility) accounts for 38% of all rifampin-resistant tuberculosis (RR-TB) in South Africa and is increasing. We aime...
Journal Article
|
Research

Whole genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high burden settings: a retrospective cohort study

Cox HS, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A,  et al.
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Journal Article
|
Research

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa

Mohr-Holland E, Reuter A, Furin J, Garcia-Prats AJ, De Azevedo V,  et al.
2020-03-01 • eClinicalMedicine
2020-03-01 • eClinicalMedicine
BACKGROUND
Limited data exist on the use of bedaquiline and delamanid in adolescents with rifampicin-resistant tuberculosis (RR-TB). We describe RR-TB treatment of adolescents (10-19...
Journal Article
|
Research

Causes of loss to follow-up from drug-resistant TB treatment in Khayelitsha, South Africa

Memani B, Beko B, Dumile N, Mohr-Holland E, Daniels J,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
Patients initiated on drug-resistant TB (DR-TB) treatment in 2019 in Khayelitsha, South Africa, with a loss to follow-up outcome were evaluated to better understand reasons for loss to f...
Journal Article
|
Letter

Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa"

Mohr-Holland E, Reuter A, Hughes J, Daniels J, Beko B,  et al.
2020-07-01 • European Respiratory Journal
2020-07-01 • European Respiratory Journal
Journal Article
|
Research

“This is not my body:” Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis

Loveday M, Hlangu S, Larkan LM, Cox HS, Daniels J,  et al.
2021-10-18 • PLOS One
2021-10-18 • PLOS One
BACKGROUND
There are few data on the on post-treatment experiences of people who have been successfully treated for rifampicin-resistant (RR-)TB.

OBJECTIVE
To describe ...
Journal Article
|
Letter

Diagnosis patterns for rifampin-resistant TB after onset of COVID-19

Mohr-Holland E, Hacking D, Daniels J, Scott V, Mudaly V,  et al.
2021-09-01 • International Journal of Tuberculosis and Lung Disease
2021-09-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Letter

A home-based care programme for rifampicin-resistant TB

Douglas-Jones B, Mohr-Holland E, Mema N, Mathee S, Mathews G,  et al.
2021-07-01 • International Journal of Tuberculosis and Lung Disease
2021-07-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Commentary

Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic

Mohr-Holland E, Douglas-Jones B, Apolisi I, Ngambu N, Mathee S,  et al.
2021-03-01 • Lancet Child and Adolescent Health
2021-03-01 • Lancet Child and Adolescent Health
Journal Article
|
Commentary

Barriers and solutions to finding rifampicin-resistant tuberculosis cases in older children and adolescents

Mohr-Holland E, Apolisi I, Reuter A, De Azevedo V, Hill JE,  et al.
2019-12-21 • Public Health Action
2019-12-21 • Public Health Action
Little is known about the barriers to post-exposure management of rifampicin-resistant tuberculosis (RR-TB) in older children and adolescents. We report on implementation lessons from a ...